Literature DB >> 11839369

Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia.

Ronnen H Segman1, Uriel Heresco-Levy, Avi Yakir, Tanya Goltser, Rael Strous, David A Greenberg, Bernard Lerer.   

Abstract

BACKGROUND: Tardive dyskinesia is a chronic adverse effect of anti psychotic drugs, where association with a polymorphic site in the dopamine D3 receptor gene has been previously reported. Cytochrome P 450 17alpha-hydroxylase activity has been implicated with modulation of central dopamine release as well as neuroprotection. We investigated the association of a T -->C variation in the cytochrome P 450 17alpha-hydroxylase gene with tardive dyskinesia in patients with chronic schizophrenia.
METHODS: Cytochrome P 450 17 allele and genotype frequencies were compared between matched schizophrenia patients with (n = 55) or without tardive dyskinesia (n = 58). Interactive effects of cytochrome P 450 17alpha-hydroxylase with the dopamine D3 Ser9Gly polymorphism on abnormal involuntary movements were examined.
RESULTS: There was no difference in cytochrome P 450 17alpha-hydroxylase genotype distribution between patients with and without tardive dyskinesia; however, patients carrying the cytochrome P 450 17alpha-hydroxylase A2-A2 genotype and the dopamine D3gly allele had the highest orofacial (p <.04), distal (p <.05), and incapacitation (p <.04) scores on the Abnormal Involuntary Movements Scale.
CONCLUSIONS: Schizophrenia patients who carry the dopamine D3gly allele and the cytochrome P 450 17alpha-hydroxylase A2-A2 genotype may be more likely to develop abnormal orofoacial and distal involuntary movements and to be incapacitated by these movements when chronically exposed to classical antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839369     DOI: 10.1016/s0006-3223(01)01302-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

Review 1.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 2.  Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation.

Authors:  Bernard Lerer; Ronnen H Segman
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 3.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

4.  Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

Authors:  Maju M Koola; Evangelia M Tsapakis; Padraig Wright; Shubulade Smith; Robert W Kerwin Rip; Katie L Nugent; Katherine J Aitchison
Journal:  J Psychopharmacol       Date:  2014-03-04       Impact factor: 4.153

Review 5.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

6.  Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study.

Authors:  P Roberto Bakker; Asmar F Y Al Hadithy; Najaf Amin; Cornelia M van Duijn; Jim van Os; Peter N van Harten
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.